BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 10, 2009
View Archived Issues
Vivus Soars Over Obesity Finish Line, Jumps into Partner Race
Vivus Inc. wowed analysts and investors on Wednesday with better-than-expected data from its final two Phase III trials of obesity drug Qnexa (phentermine/topiramate CR). (BioWorld Today)
Read More
Health Care Tax on Biotechs Drawing Concern from BIO
Read More
In Separate Studies, Two New Genes Tied to Hearing Loss
Read More
Targeted Genetics Gets $7M Lifeline in Genzyme Deal
Read More
CellCyte, Ex-Officers Charged with Misleading Shareholders
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Financings Roundup
Read More